Combating T-cell Dysfunction in Cutaneous Squamous Cell Carcinoma: Integrating Checkpoint Inhibitors into Clinical Practice and Managing Adverse Events
Todd E. Schlesinger, MD, FAAD
Director, Dermatology and Laser Center of Charleston, Clinical Research Center of the Carolinas
Clinical Instructor, University at Buffalo Department of Dermatology
Affiliate Assistant Professor, Medical University of South Carolina Department of Family Medicine
Clinical Preceptor, Medical University of South Carolina College of Health Professions
This enduring activity is focused on the management of patients with advanced or metastatic cutaneous squamous cell carcinoma.
This activity is designed to meet the educational needs of surgical dermatologists, dermatologists, and other healthcare practitioners who care for patients with advanced or metastatic cutaneous squamous cell carcinoma.
After completing the CME activity, learners should be better able to:
- Describe the mechanism of action of checkpoint inhibitors and the impact of high tumor mutational burden and tumor-infiltrating lymphocytes on treatment outcomes
- Identify patients with cSCC who are at high-risk of recurrence or metastasis and apply recommendations from current treatment guidelines to minimize risk
- Review clinical trial data supporting the use of checkpoint inhibitors in the management of cutaneous squamous cell carcinoma
- Recognize and manage immune-related adverse events (irAEs) associated with checkpoint inhibitors
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with advanced or metastatic cutaneous squamous cell carcinoma.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Todd E. Schlesinger, MD, FAAD, has received grants/research funding from AbbVie, Aclaris, Amgen, Astellas Pharma US, Inc., Akros, Allergan, Bayer, Biofrontera, Boehringer-Ingelheim, Bristol-Meyers Squibb, Celgene, Centocur Ortho Biotech, Inc., Coherus Biosciences, Corrona, Dermira, Dermavant, Galderma (Nestle), Genentench, Inc., Janssen Pharmaceuticals, Inc., Kinex, Kiniksa, Leo, Lilly, Merz, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sebacia, Sienna Biopharmaceuticals, Sisaf, and Valeant Pharmaceuticals North America, LLC. Dr. Schlesinger has consulted for AbbVie Inc., (honoraria), Aclaris (honoraria), Allergan (honoraria), Bristol-Meyers Squibb (honoraria), Galderma (honoraria), Innocutis (salary), Lilly (fees), Merz (honoraria), Novartis (honoraria), Ortho Dermatologics, Pharmatecture, Prolacta Bioscience, Regeneron Pharmaceuticals, Inc. (fees), Sun Pharma, and Unilever (honoraria). Dr. Schlesinger has served on the speakers’ bureau for Aclaris, Almirall, Bayer (honoraria), Dermira (honoraria), Ilumya, LIBTAYO, ODOMZO, Regeneron Pharmaceuticals, Inc. (honoraria), Rhofade, Sanofi Genzyme, Suneva (honoraria), and Sun Pharma (honoraria). He is on the Advisory Board for Almirall (honoraria), Bioderma (honoraria), Biofrontera AG (honoraria) Greenway Therapeutix (no compensation), Remedly, Inc. (stock options), and Suneva Medical, Inc. (honoraria).
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Melissa A Johnson, Sr. Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director of Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the activity; and
3. Complete pre-and-post surveys and evaluation.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: January 31, 2020
EXPIRATION DATE: January 31, 2021
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.